Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ERBIN_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ERBIN_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ERBIN_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/ERBIN_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ERBIN_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ERBIN_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ERBIN_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ERBIN_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ERBIN_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ERBIN_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00324967 | Lung | IAC | response to lipopolysaccharide | 53/2061 | 343/18723 | 6.87e-03 | 4.75e-02 | 53 |
GO:00451975 | Lung | IAC | establishment or maintenance of epithelial cell apical/basal polarity | 11/2061 | 44/18723 | 6.90e-03 | 4.75e-02 | 11 |
GO:000716313 | Lung | AIS | establishment or maintenance of cell polarity | 56/1849 | 218/18723 | 1.31e-11 | 6.13e-09 | 56 |
GO:005105611 | Lung | AIS | regulation of small GTPase mediated signal transduction | 66/1849 | 302/18723 | 4.26e-10 | 9.53e-08 | 66 |
GO:000717312 | Lung | AIS | epidermal growth factor receptor signaling pathway | 29/1849 | 108/18723 | 3.99e-07 | 3.23e-05 | 29 |
GO:003052213 | Lung | AIS | intracellular receptor signaling pathway | 53/1849 | 265/18723 | 4.57e-07 | 3.55e-05 | 53 |
GO:000722912 | Lung | AIS | integrin-mediated signaling pathway | 28/1849 | 107/18723 | 1.11e-06 | 7.51e-05 | 28 |
GO:003812712 | Lung | AIS | ERBB signaling pathway | 30/1849 | 121/18723 | 1.60e-06 | 9.91e-05 | 30 |
GO:000726512 | Lung | AIS | Ras protein signal transduction | 60/1849 | 337/18723 | 4.68e-06 | 2.31e-04 | 60 |
GO:004657812 | Lung | AIS | regulation of Ras protein signal transduction | 39/1849 | 189/18723 | 6.68e-06 | 2.95e-04 | 39 |
GO:009907211 | Lung | AIS | regulation of postsynaptic membrane neurotransmitter receptor levels | 18/1849 | 62/18723 | 1.94e-05 | 6.70e-04 | 18 |
GO:003508811 | Lung | AIS | establishment or maintenance of apical/basal cell polarity | 13/1849 | 49/18723 | 7.13e-04 | 1.04e-02 | 13 |
GO:006124511 | Lung | AIS | establishment or maintenance of bipolar cell polarity | 13/1849 | 49/18723 | 7.13e-04 | 1.04e-02 | 13 |
GO:000660513 | Lung | AIS | protein targeting | 49/1849 | 314/18723 | 8.56e-04 | 1.17e-02 | 49 |
GO:005109011 | Lung | AIS | regulation of DNA-binding transcription factor activity | 64/1849 | 440/18723 | 1.04e-03 | 1.36e-02 | 64 |
GO:004519711 | Lung | AIS | establishment or maintenance of epithelial cell apical/basal polarity | 11/1849 | 44/18723 | 3.01e-03 | 2.97e-02 | 11 |
GO:003461212 | Lung | AIS | response to tumor necrosis factor | 39/1849 | 253/18723 | 3.40e-03 | 3.23e-02 | 39 |
GO:007135612 | Lung | AIS | cellular response to tumor necrosis factor | 35/1849 | 229/18723 | 6.08e-03 | 4.98e-02 | 35 |
GO:000716323 | Lung | AAH | establishment or maintenance of cell polarity | 24/613 | 218/18723 | 2.21e-07 | 1.01e-04 | 24 |
GO:003508821 | Lung | AAH | establishment or maintenance of apical/basal cell polarity | 9/613 | 49/18723 | 2.60e-05 | 3.42e-03 | 9 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ERBIN | SNV | Missense_Mutation | novel | c.2410A>T | p.Thr804Ser | p.T804S | Q96RT1 | protein_coding | tolerated_low_confidence(0.67) | benign(0.007) | TCGA-A8-A06U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ERBIN | SNV | Missense_Mutation | | c.1396N>A | p.Glu466Lys | p.E466K | Q96RT1 | protein_coding | deleterious(0.01) | benign(0.186) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ERBIN | SNV | Missense_Mutation | rs144581883 | c.3389N>A | p.Arg1130Gln | p.R1130Q | Q96RT1 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ERBIN | SNV | Missense_Mutation | | c.3872N>T | p.His1291Leu | p.H1291L | Q96RT1 | protein_coding | deleterious(0) | benign(0.331) | TCGA-AO-A0JJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophospamide | SD |
ERBIN | SNV | Missense_Mutation | novel | c.1765N>A | p.Val589Ile | p.V589I | Q96RT1 | protein_coding | tolerated(0.23) | benign(0) | TCGA-B6-A40B-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ERBIN | SNV | Missense_Mutation | | c.4072N>A | p.Asp1358Asn | p.D1358N | Q96RT1 | protein_coding | deleterious(0.02) | probably_damaging(0.917) | TCGA-BH-A0AZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |
ERBIN | SNV | Missense_Mutation | | c.907N>C | p.Glu303Gln | p.E303Q | Q96RT1 | protein_coding | deleterious(0) | possibly_damaging(0.744) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
ERBIN | SNV | Missense_Mutation | | c.2631N>C | p.Glu877Asp | p.E877D | Q96RT1 | protein_coding | tolerated(0.94) | benign(0.022) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
ERBIN | SNV | Missense_Mutation | | c.3049N>A | p.Glu1017Lys | p.E1017K | Q96RT1 | protein_coding | tolerated(0.2) | benign(0.278) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
ERBIN | SNV | Missense_Mutation | | c.3268N>T | p.Asp1090Tyr | p.D1090Y | Q96RT1 | protein_coding | deleterious(0) | possibly_damaging(0.653) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |